



BIOHEART

Media Contact: Bioheart, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 954.835.1500
bioheart@bioheartinc.com

For Immediate Release

Bioheart Highlights Positive First Quarter Results

Sunrise, FL – May 6, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB) highlights today the positive results from its first quarter 2015 operations:

1. Revenues for the quarter ending March 31, 2015 increased 24.8% or \$97,183 to \$490,000 over the same period in 2014.
2. Cash and cash equivalents used in operations for the quarter ending March 31, 2015 remained relatively constant increasing to \$384,000 in 2015 from \$258,000 in 2014. The majority of the quarterly increase is attributable to periodic accounting and legal expenses.
3. Current liabilities as of March 31, 2015 decreased 2.7% or \$306,000 to \$11.1 million.
4. The Company's working capital deficit as of March 31, 2015 improved \$100,000 (0.9%) to \$11.0 million.

“We continue to advance on our plan and pathway to profitability,” said **Mike Tomas, President and Chief Executive Officer**. “Each of our operating divisions: Bioheart, US Stem Cell Training, Vetbiologics and US Stem Cell Clinic have made strategic and tactical gains in the first quarter and we expect to build on our positive momentum as we continue through this year. Physician, patient and veterinarian demand for our products and services continue to expand. To this point, product and service sales growth have emanated from organic, viral communications amongst our network of physicians and patients. To move beyond organic growth to accelerated growth, we are investigating several new marketing initiatives including but not limited to new branding strategies, new pricing strategies, new patient treatment financing options as well as upgrades to our websites and new B-to-B and B-to-C marketing campaigns. We recently announced increases to our staff to facilitate current and future anticipated sales growth. We remain confident in our abilities and steadfast on our objectives and desire to create positive outcomes for our patients and positive investment outcomes for our shareholders.”

About Bioheart, Inc.

Bioheart, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of

a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

US Stem Cell Training, (“SCT”), an operating division of Bioheart, Inc., is a content developer of regenerative medicine / cell therapy informational and training materials for physicians and patients. SCT also provides in-person and online training courses which are delivered through in-person presentations at SCT’s state of the art facilities and globally at university, hospital and physician’s office locations as well as through online webinars. Additionally, SCT provides hands-on clinical application training for physicians and health care professionals interested in providing regenerative medicine / cell therapy procedures.

Vetbiologics, (“VBI”), an operating division of Bioheart, Inc., is a veterinary regenerative medicine company committed to providing veterinarians with the ability to deliver the highest quality regenerative medicine therapies to dogs, cats and horses. VBI provides veterinarians with extensive regenerative medicine capabilities including the ability to isolate regenerative stem cells from a patient’s own adipose (fat) tissue directly on-site within their own clinic or stall-side. VBI regenerative medicine technologies are designed, implemented and produced according to the highest standards. VBI follows the FDA guidelines for human cellular therapy production which means each product produced must be validated and must pass stringent criteria.

US Stem Cell Clinic, LLC, (“SCC”), a partially owned investment of Bioheart, Inc., is a physician run regenerative medicine / cell therapy clinic providing cellular treatments for patients afflicted with neurological, autoimmune, orthopedic and degenerative diseases. SCC is operating in compliance with the FDA 1271s which allow for same day medical procedures to be considered the practice of medicine. We isolate stem cells from bone marrow and adipose tissue and also utilize platelet rich plasma.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2014, and its Quarterly Reports on Form 10-Q.